Innovative Sequence of Docetaxel–Gemcitabine Based on Preclinical Data in the Treatment of Advanced Non-Small Cell Lung Cancer: A Phase I Study

    February 2005 in “ Lung Cancer ”
    Toni Ibrahim, Wainer Zoli, Giovanni Luca Frassineti … Dino Amadori
    Studysummary The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on lungcancerjournal.info →
    Discuss this study in the Community →